ALXO
ALX Oncology Holdings Inc.
There isn't enough reported data to score ALXO yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
ALXO Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
ALXO's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
ALXO PE Valuation
ALXO has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
ALXO Forward outlook
There aren't enough analyst estimates for ALXO to show an outlook.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
ALXO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.13 | +$1.05 |
| Q1 2026 | -$1.49 | +$0.96 |
| Q4 2025 | -$1.90 | +$0.68 |
| Q3 2025 | -$2.01 | +$0.96 |
| Q2 2025 | -$2.18 | +$1.45 |
| Q1 2025 | -$2.45 | +$1.26 |
| Q4 2024 | -$2.58 | +$1.16 |
| Q3 2024 | -$2.97 | +$0.60 |
ALXO is still losing money, but far less than before: $1.13 per share over the past year, against $3.74 at its worst in late 2023.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over ALXO on earnings quality, reporting a profit while its opponent remains loss making.
ALXO Quarterly Revenue
UNH has the edge over ALXO in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2020 | -2047% | N/A |
| Q1 2020 | -800% | N/A |
| Q4 2019 | -638% | N/A |
| Q3 2019 | -242% | N/A |
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over ALXO in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
ALXO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$16.1M | +$7.4M |
| Q1 2026 | -$18.7M | +$6M |
| Q4 2025 | -$19M | +$13.1M |
| Q3 2025 | -$17.1M | +$8.4M |
| Q2 2025 | -$23.5M | +$3.2M |
| Q1 2025 | -$24.7M | +$13.3M |
| Q4 2024 | -$32.1M | +$7.7M |
| Q3 2024 | -$25.5M | +$4.3M |
ALXO has burned cash in almost every quarter: −$71M over the past year, against −$106M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over ALXO on cash generation, producing positive trailing cash flow while its opponent burns cash.
ALXO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +30% | +31.1M shares |
| 1 year | +154% | +82.3M shares |
| 3 years | +232% | +94.8M shares |
| 5 years | +239% | +95.6M shares |
| Available history | +518% | +114M shares |
ALXO has 136M diluted shares, up 154% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2020 | — |
| Q4 2019 | — |
| Q3 2019 | — |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over ALXO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
ALXO Net Leverage
ALXO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
ALXO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.3 | Neutral |
| Stochastic | 22.2 | Neutral |
ALXO's weekly RSI is 34 (neutral) and its Stochastic is 22 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
ALXO PE vs Healthcare Sector
ALXO has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
ALXO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.18 | 8.5% below |
| 20 week MA | $1.67 | 35% below |
| 50 week MA | $1.73 | 38% below |
| 100 week MA | $1.38 | 22% below |
| 200 week MA | $4.50 | 76% below |
ALXO is in a downtrend: it's below all five of its weekly moving averages, and 76% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over ALXO on trend strength, trading above more of its moving averages.
ALXO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $30.0 | $88.6 | +195% |
| 2021 | $88.6 | $23.3 | -74% |
| 2022 | $23.3 | $11.1 | -52% |
| 2023 | $11.1 | $14.9 | +34% |
| 2024 | $14.9 | $1.62 | -89% |
| 2025 | $1.62 | $1.33 | -18% |
| 2026 YTD | $1.33 | $1.08 | -19% |
ALXO's yearly returns have swung widely, from +195% in 2020 to −89% in 2024. It's down 19% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over ALXO on returns for 2026, with the stronger performance.